ardiance (empagliflozin), a drug developed as a glucose-lowering treatment for type 2 diabetes, has been shown to slow the progression of chronic kidney disease in a new study published in The
STUDY: JARDIANCE SLOWS KIDNEY DISEASE
Feb 18, 2023
1 minute
You’re reading a preview, subscribe to read more.
Start your free 30 days